ANDOVER,
Mass., Sept. 27, 2024 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart, and liver failure, today announced
that on September 24, 2024,
TransMedics granted non-qualified stock options to purchase an
aggregate of 336 shares of its common stock and an aggregate of 218
restricted stock units to 1 employee, each as a material inducement
for the employee's entry into employment with TransMedics. The
grants were approved by the Compensation Committee of the
TransMedics Board of Directors and were granted in accordance with
Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics
Group, Inc. Inducement Plan.
TransMedics granted non-qualified stock options to purchase 336
shares of TransMedics' common stock and 218 restricted stock units
in the aggregate. The stock options were granted with a per share
exercise price of $156.00, the
closing price of the common stock on the Nasdaq Global Market on
September 24, 2024. Twenty-five
percent of the shares subject to each option will vest on the first
yearly anniversary of the date of the employee's start of
employment, with the remainder vesting in equal monthly
installments over the subsequent three year period, subject to the
employee's continued service with the Company through the
applicable vesting date. The options have a 10-year term and are
subject to the terms of the TransMedics Group, Inc. Inducement
Plan. Twenty-five percent of each restricted stock unit award will
vest on the first four anniversaries of the date of the employee's
start of employment, subject to the employee's continued service
with the Company through the applicable vesting date. The
restricted stock units are subject to the terms of the TransMedics
Group, Inc. Inducement Plan.
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian
Johnston
332-895-3222
Investors@transmedics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302260563.html
SOURCE TransMedics Group, Inc.